ArticleJournal of neuromuscular diseases2026
Myotonic dystrophy family registry. The patient experience.
Article in Journal of neuromuscular diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThe Myotonic Dystrophy Family Registry (MDFR) is a disease-specific, patient-reported online registry designed to capture real-world data on disease burden and lived experience in myotonic dystrophy (DM). By integrating patient-reported data with mechanisms for participant engagement, the MDFR provides a platform to characterize disease heterogeneity and support clinical research and trial readiness.AimsTo characterize patient-reported disease burden and registry participation in DM, and to explore associations between disease subtype, age-related variables, and repeat expansion length.MethodsDe-identified MDFR data collected between 2013 and 2024 were aggregated and analyzed. Patient demographics and symptom prevalence were tested for associations between DM subtype, age, and repeat expansion length.ResultsThe analysis demonstrated substantial, age-dependent disease burden in both DM1 and DM2, with multisystem involvement across central nervous system, cardiac, pulmonary, visual, and neuromuscular domains. Daytime sleepiness, myotonia, and fatigue were among the most frequently reported manifestations. Significant genotype-phenotype associations were identified in DM1, with CTG repeat length associated with increased prevalence of motor, cardiac, and central nervous system manifestations.ConclusionsPatient-reported data from the MDFR provide complementary insights into disease burden and heterogeneity in DM, including domains that may be underrepresented in clinically derived datasets. Going forward, these findings support the integration of patient-reported, clinical, and genetic data to improve disease characterization, inform clinical trial design, and advance therapeutic development. Continued efforts to harmonize and expand longitudinal data collection and standardize data elements will be important to enhance the utility of registries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.